Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Lawsuit

Law firm alerts shareholders of ongoing legal action against gene therapy company uniQure.

Apr. 2, 2026 at 6:33pm

Got story updates? Submit your updates here. ›

Bernstein Liebhard LLP, a national law firm, has issued a shareholder alert reminding investors of an ongoing lawsuit against uniQure N.V., a gene therapy company. The alert informs uniQure shareholders about the legal proceedings and encourages them to participate in the case.

Why it matters

Shareholder lawsuits can have significant impacts on public companies, potentially leading to financial penalties, legal costs, and reputational damage. This alert suggests there may be concerns about uniQure's business practices or disclosures that have prompted legal action from investors.

The details

The alert from Bernstein Liebhard LLP does not provide specifics on the nature of the lawsuit or the allegations against uniQure. However, it does encourage uniQure shareholders to contact the law firm to learn more about participating in the case and protecting their investment interests.

  • The shareholder alert was issued on April 2, 2026.

The players

Bernstein Liebhard LLP

A national law firm that specializes in representing investors in class action lawsuits.

uniQure N.V.

A gene therapy company that develops treatments for rare genetic disorders.

Got photos? Submit your photos here. ›

What’s next

The alert does not provide any information about specific next steps in the legal proceedings. Shareholders interested in participating in the case would need to contact Bernstein Liebhard LLP directly.

The takeaway

This shareholder alert suggests there may be ongoing legal concerns about uniQure's business practices or disclosures that have prompted a lawsuit. The outcome of this case could have significant financial and reputational implications for the gene therapy company.